Andy Wang

Practice Areas

Andy is a partner of Dentons Shanghai office who specializes in mergers & acquisitions, licensing projects, anti-bribery, data protection, anti-trust, advertisement, and regulatory requirements with a focus on the industries of life sciences and healthcare.

Career

2012 to date: Dentons Shanghai, partner

Sep 2011– June 2012: seconded counsel at Siemens

2007 – 2011: Pinsent Masons LLP, associate

2005 – 2007: Ingersoll Rand, regional counsel for China

2000 – 2005: Allen & John Law Firm, lawyer

Professional Memberships

Member of Shanghai Lawyers Association

Publications

• A series of articles on the topic of new medical device regulations in China (2021)

• “The Legal Pathway for Drug Marketing Authorization Transfer under MAH System”(2021)

• “Inspection Manual for the Update of Clinical Trial Agreement” (2020)

• “Compliance Control of Indirect Third Parties in Pharma and Medical Device Industries”(2020)

• “How to Get Medical Product Quickly Approved for COVID-19 in China?” (2020)

• “A brief Introduction to Compliance Management of RUO Products in China” (2019)

• “Observations on Highlights of China’s New Rule on Human Genetic Resources” (2019)

• “Health Data Protection in China – Part I and II” (2018)

• “2017 Year in Review - Penalty Counting for Pharmaceutical Industry in Shanghai”(2018)

• “China’s New Round of Reform of Accelerating Regulatory Approval on Medical Products” (2017)

• “Kill the Black Swans - Probably a Revolutionary Change in the Antibribery Regime in China” (2017)

• “Revenue-Based Commission - a Risk for CSO” (2017)

• “Summary of Local Policies to Implement Two-invoice System in Healthcare Industry and Our Observation” & “National Version of Two-invoice System” (2017)

• “2016 Year in Review – Penalty Counting for Medical Institutions in Shanghai” (2017)

• “Penalty Counting for Pharmaceutical, Medical Device Companies and Drug Stores in Shanghai” (2017)

• “New Features Introduced by New Medical Device Recall Measures” (2017)

• “Latest Changes in China’s Administration on Internet-based Pharmaceutical Trading” (2017)

• “In-Progress Reform of China’s Approval Regime on Medical Products” (2017)

• “China’s 3-Year-Old Medial Device Regulations Changed” (2017)

• “Where is the Safe Harbour?-Preliminary Analysis of Loyalty Discounts in the Tetra Pak’s Penalty Case” published on CCH in 2016

• “What China Should Learn from GDPR on Protection of Health Data” published on CCH in 2016

• “How Foreign Investors Invest in the Chinese Genetic Diagnosis and Therapy Industries” published on CCH in 2016

• “What Healthcare Players Could Learn from the Anti-Trust Guideline for Automobile Industry (Draft for Comments)” published on CCH in 2016

• “How China Protects Personal Data Concerning Health” published on CCH in 2016

• “How Non-Hong Kong, Macao or Taiwan Foreign Investors Set Up a Medical Institution in the Form of WFOE in China” published on CCH in 2016

• “Red-Letter VAT Invoice A Safe Harbor for Sales Rebates” published on CCH in 2016

• "AppleWatch, Medical Device?" published on CCH and LexisNexis in April 2015

• "The Implications to the Life Science Sectors of 2015 Edition Foreign Investment Industries Catalog" publised on CCH and LexisNexis in March 2015

• "The Three Misreading on China's Regulatory Requirement on Gene Testing Business" published on LexiNexis in Jan 2015

• "What Can We Benefit from the New Medical Device Regulations" (bilingual) published on LegalSutdio in April 2014